テムシロリムス 価格 もっと(14)

メーカー	製品番號	製品説明	CAS番號	包裝	価格	更新時(shí)間	購入
富士フイルム和光純薬株式會(huì)社(wako)	W01TRCT017960	テムシロリムス (?90%) Temsirolimus (?90%)	162635-04-3	50mg	￥134100	2024-03-01	購入
富士フイルム和光純薬株式會(huì)社(wako)	W01TOC5264	Temsirolimus	162635-04-3	10mg	￥59000	2024-03-01	購入
富士フイルム和光純薬株式會(huì)社(wako)	W01TRCT017960	テムシロリムス (?90%) Temsirolimus (?90%)	162635-04-3	5mg	￥25300	2023-06-01	購入
東京化成工業(yè)	T3574	テムシロリムス >95.0%(HPLC) Temsirolimus >95.0%(HPLC)	162635-04-3	50mg	￥45200	2024-03-01	購入
Sigma-Aldrich Japan	PZ0020	テムシロリムス ≥98% (HPLC) Temsirolimus ≥98% (HPLC)	162635-04-3	5mg	￥25600	2024-03-01	購入

テムシロリムス 化學(xué)特性,用途語,生産方法

外観

白色～わずかにうすい褐色、結(jié)晶～粉末

溶解性

エタノール(99.5)に溶けやすく、水にほとんど溶けない。

用途

mTOR 阻害剤で、乳がん細(xì)胞株において腫瘍の成長を阻害します（IC50=1.6 nmol/l（SKBr3），4.3 nmol/l（BT474））。

効能

抗悪性腫瘍薬, mTOR阻害薬

商品名

トーリセル (ファイザー)

説明

While renal cell carcinoma (RCC) accounts for only 2 3% of all cancers, the 5-year survival rate for advanced RCC disease is only 5 10%, with approximately 13,000 deaths occurring annually (US statistics only). Immunotherapeutic cytokine options, such as IFN-αand IL-2, have traditionally been frontline treatments, but these agents are not efficacious in all patients and can cause serious side effects. In addition, bevacizumab, a monoclonal antibody against VEGF, has also demonstrated prolongation of PFS. The newest entry for this indication focuses on targets that are downstream from VEGF. Temsirolimus is an inhibitor of the serine/threonine kinase mTOR, which is the mammalian target of rapamycin. mTOR has been implicated in cell replication through control of the cell cycle translation of specific mRNAs. Inhibition of mTOR prevents phosphorylation of the 4E binding protein-1 and the 40S ribosomal protein S6 kinase that are responsible for cell cycle protein translation initiation; cell cycle arrest occurs as the result of termination of cell division from the G1 to the S phase. Disruption of mTOR signaling also has antiangiogenic effects that could be deemed essential in combating RCC, which is driven by unregulated angiogenesis. Temsirolimus is the 2,2-bis(hydroxymethyl)propionate ester of rapamycin (sirolimus), a macrolide fungicide isolated from the bacteria Streptomyces hygroscopicus. Similar to its parent sirolimus, temsirolimus interacts with mTOR through its complex with FK-506 binding protein 12.

化學(xué)的特性

White Solid

使用

Temsirolimus, a cell cycle inhibitor developed by Wyeth for the treatment of renal cell carcinoma, was launched in the US in 2007. Temsirolimus works by inhibiting mTOR (mammalian target of rapamycin)-driven cell proliferation. Temsirolimus is also being developed for the treatment of mantle cell lymphoma (PhIII) and also as mono- or combination therapy for the treatment of ovarian and endometrium cancer (PhII). Additionally, temsirolimus is being evaluated for the treatment of several other types of cancer as well as multiple sclerosis and rheumatoid arthritis.

一般的な説明

Temsirolimus is an esterified derivative of rapamycinand in a similar manner binds initially to the proteinFKBP-12(FK506-binding protein).This complexthen acts to inhibit the mammalian target of rapamycin(mTOR), a serine-threonine kinase that plays a crucial rolein cell division. It is somewhat unique in its method of kinaseinhibition, because it actually binds to an allostericmodulator of the kinase rather than just binding to theATP-binding site like most other kinase inhibitors.Temsirolimus is available as a 25-mg/mL injection forIV administration in the treatment of advanced RCC. Theagent is extensively metabolized and undergoes rapid hydrolysisof the ester function to give rapamycin that retainsactivity.Additional metabolism is mediated primarilyby CYP3A4 to give several hydroxylated and demethylatedmetabolites that are inactive. The agent and metabolites areeliminated primarily in the feces with half-lives of 17 and55 hours for temsirolimus and rapamycin, respectively.This agent, like rapamycin, possesses immunosuppressantproperties and there is an increased risk of infection.The most serious side effects are interstitial lung disease,perforation of the bowel, and acute renal failure althoughthese occur only rarely. The most commonly seen side effects are rash, weakness, mucositis, nausea, edema, andanorexia.

テムシロリムス 上流と下流の製品情報(bào)

原材料

準(zhǔn)備製品

テムシロリムス 生産企業(yè)

名前	電話番號	電子メール	國籍	製品カタログ	優(yōu)位度
Hebei Chuanghai Biotechnology Co., Ltd	+86-15350571055	Sibel@chuanghaibio.com	China	8738	58
Henan Bao Enluo International TradeCo.，LTD	+86-17331933971	deasea125996@gmail.com	China	2472	58
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21585	55
Shanghai Yingrui Biopharma Co., Ltd.	+86-21-33585366 - 03@	sales03@shyrchem.com	CHINA	738	60
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	33024	60
career henan chemical co	+86-0371-86658258	sales@coreychem.com	China	29812	58
Biochempartner	0086-13720134139	candy@biochempartner.com	CHINA	965	58
Xiamen AmoyChem Co., Ltd	+86-86-5926051114	sales@amoychem.com	China	6366	58
NanJing Spring & Autumn Biological Engineering CO., LTD.	+8613815430202	sale02@cqherb.com	CHINA	376	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19936	58

162635-04-3(テムシロリムス)キーワード:

---

• 162635-04-3
• 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropa
• Temsirolimus(CCI-779)
• TEMSIROLIMUS
• CCL-779
• Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate
• TeMsiroliMus (CCI-779, Torisel)
• rapaMycin 42-ester with 3-hydroxy-2-(hydroxyMethyl)-2-Methylpropionic acid
• 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin
• C15182
• TeMsiroliMus (Torisel)
• TeMsiroliMus (~90%)
• TeMsiroliMus (Torisel,CCI-779,NSC-683864)
• TeMsiroliMus (CCI-779, NSC 683864)
• Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate Temsirolimus
• Temsirolimus Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
• 42-[3-Hydroxy-2-methylpropanoate
• Temsirolimus, >=98%
• NSC 683864
• (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
• Temsirolimus (mixture of isomers)
• Temsirolimus USP/EP/BP
• TemsirolimusQ: What is Temsirolimus Q: What is the CAS Number of Temsirolimus Q: What is the storage condition of Temsirolimus Q: What are the applications of Temsirolimus
• 162635-04-3 Temsirolimus
• temsirolimus 162635-04-3
• CCI-779; NSC 683864
• CS-442
• Simultaneous
• 40-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin
• (1R,2R,4R)-4-((R)-2-((3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-Dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1]oxa[4]azacyclohentriacontin-3-yl)propyl)-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
• NSC 683864|||CCI-779
• テムシロリムス
• ラパマイシン42-[3-ヒドロキシ-2-(ヒドロキシメチル)-2-メチルプロパノアート]
• テムシロリムス (?90%)
• テムシロリムス(異性體混合物)
• テムシロリムス (CCI-779, Torisel)
• テムシロリムス (JAN)
• CCI-779
• (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-ジヒドロキシ-19,30-ジメトキシ-15,17,21,23,29,35-ヘキサメチル-2,3,10,14,20-ペンタオキソ-11,36-ジオキサ-4-アザトリシクロ[30.3.1.04,9]ヘキサトリアコンタ-16,24,26,28-テトラエン-12-イル]プロピル]-2-メトキシシクロヘキシル 3-ヒドロキシ-2-(ヒドロキシメチル)-2-メチルプロパノアート
• テンシロリムス
• (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-ジヒドロキシ-15,17,21,23,29,35-ヘキサメチル-12-[(1R)-1-メチル-2-[(1S)-3β-メトキシ-4α-[2,2-ビス(ヒドロキシメチル)プロピオニルオキシ]シクロヘキサン-1β-イル]エチル]-19,30-ジメトキシ-11,36-ジオキサ-4-アザトリシクロ[30.3.1.04,9]ヘキサトリアコンタン-16,24,26,28-テトラエン-2,3,10,14,20-ペンタオン